Moderna's stock surged more than 110% following the announcement of positive Phase 3 results for its personalized mRNA cancer vaccine, according to market reports. The share price had already nearly doubled after the initial news, and the continued climb reflects strong investor confidence in the breakthrough treatment, developed in partnership with Merck.
Moderna's stock (NASDAQ: MRNA) continued its rally Wednesday, trading more than 110% higher after the company announced positive Phase 3 results for its personalized mRNA cancer vaccine, according to financial reports.
The Zioneer had reported at 17:13 Jerusalem that the stock had nearly doubled after Moderna and partner Merck unveiled the Phase 3 data in melanoma, showing the vaccine significantly delayed cancer recurrence and spread. The shares have since extended those gains.
The treatment is the first ever personalized mRNA cancer vaccine to succeed in a Phase 3 trial and is now being tested against other cancers. The surge underscores investor confidence in the platform's potential beyond COVID-19.
4 developments
Source and signal
- Open-source intake